Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on SPS Commerce, Raises Price Target to $160

Needham Maintains Buy on SPS Commerce, Raises Price Target to $160

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:SPSC) with a Buy and raises the price target from $150 to $160.

byBenzinga Newsdesk

February 10, 2023

1 minute read

Needham analyst Scott Berg maintains SPS Commerce (NASDAQ:SPSC) with a Buy and raises the price target from $150 to $160.

Analyst Ratings

Expert Ratings for Hasbro

By Benzinga Insights

April 3, 2:01 PM

Hasbro (NASDAQ:HAS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

HAS

Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk

By Benzinga Newsdesk

August 29, 8:06 AM

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced

AEZS

Salesforce’s Downsizing Does Not Shock Analysts, See Attractive Margin Expansion From The Move

By Anusuya Lahiri

January 5, 2:52 PM

Needham analyst Scott Berg maintained Hold on Salesforce, Inc (NYSE: CRM).

CRM

Analyst Ratings

The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals

By Benzinga Insights

May 8, 2:00 PM

Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix…

IONS

Needham Maintains Buy on SPS Commerce, Raises Price Target to $160

Related Posts

Expert Ratings for Hasbro

Aeterna Zentaris Set To Regain Full Rights To Macrilen In U.S. And Canada From Novo Nordisk

Salesforce’s Downsizing Does Not Shock Analysts, See Attractive Margin Expansion From The Move

The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals